ClinicalTrials.gov
ClinicalTrials.gov Menu

Hemofiltration for Contrast-Induced Nephropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00158080
Recruitment Status : Unknown
Verified September 2005 by Nara Medical University.
Recruitment status was:  Recruiting
First Posted : September 12, 2005
Last Update Posted : September 12, 2005
Sponsor:
Information provided by:
Nara Medical University

Brief Summary:
Contrast-induced acute renal failure can be prevented with hemofiltration which is performed during cardiac catheterization

Condition or disease Intervention/treatment Phase
Chronic Kidney Disease Cardiac Catheterization Procedure: hemofiltration Not Applicable

Study Type : Interventional  (Clinical Trial)
Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Prevention of Contrast-Induced Nephropathy by Real-Time Hemofiltration

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases
U.S. FDA Resources




Primary Outcome Measures :
  1. Prevention of contrast-induced acute renal failure, Elevation of serum creatinine

Secondary Outcome Measures :
  1. Need for hemodialysis


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with serum creatinine>2.0mg/dl and/or GFR<50ml/min

Exclusion Criteria:

  • Emergent cardiac catheterization
  • Patients on chronic dialysis
  • Patients with HYHA>III heart failure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00158080


Contacts
Contact: Koji Harada, MD +81-744-22-3051 ext 3411 kzharada@naramed-u.ac.jp

Locations
Japan
First Dept of InternalMedicine, Nara Medical University Recruiting
Kashihara, Nara, Japan, 634-8522
Contact: Koji Harada, MD    +81-744-22-3051 ext 3411    kzharada@naramed-u.ac.jp   
Sponsors and Collaborators
Nara Medical University
Investigators
Study Director: Yoshihiko Saito, MD, PhD Nara Medical University

Publications:
ClinicalTrials.gov Identifier: NCT00158080     History of Changes
Other Study ID Numbers: K0001
First Posted: September 12, 2005    Key Record Dates
Last Update Posted: September 12, 2005
Last Verified: September 2005

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency